TCGA-CV-A45W-01A-11R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.319178082
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.210
- XENOBIOTIC_METABOLISM+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- OXIDATIVE_PHOSPHORYLATION+0.160
- DNA_REPAIR+0.110
- FATTY_ACID_METABOLISM+0.090
- SPERMATOGENESIS+0.080
- ALLOGRAFT_REJECTION+0.050
- MTORC1_SIGNALING+0.050
- CHOLESTEROL_HOMEOSTASIS+0.030
Top 10 suppressed
- TGF_BETA_SIGNALING-0.580
- INTERFERON_ALPHA_RESPONSE-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- MITOTIC_SPINDLE-0.400
- MYOGENESIS-0.370
- PROTEIN_SECRETION-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- APICAL_JUNCTION-0.350
- APICAL_SURFACE-0.350
- HEDGEHOG_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.817 |
| 2 | SRR934734 | — | — | 0.807 |
| 3 | HL60_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.806 |
| 4 | TCGA-UP-A6WW-01A-12R-A34R-07 | — | — | 0.805 |
| 5 | MDT-AP-1302 | Med | Medulloblastoma | 0.804 |
| 6 | TCGA-CV-A45Z-01A-21R-A24Z-07 | — | — | 0.803 |
| 7 | bd844a66-bb61-4ba1-9301-1bdeec35620f | — | — | 0.801 |
| 8 | SRR33532828 | — | B | 0.801 |
| 9 | TCGA-TN-A7HI-01A-11R-A34R-07 | — | — | 0.800 |
| 10 | SRR12202427 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |